Aclaris Therapeutics, Inc. Stock Issued During Period, Value, Acquisitions
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aclaris Therapeutics, Inc. stock issued during period, value, acquisitions for the quarter ending 2017-12-31 was $0.00.
- Aclaris Therapeutics, Inc. stock issued during period, value, acquisitions for the quarter ending 2016-12-31 was $0.00.
- Aclaris Therapeutics, Inc. stock issued during period, value, acquisitions for the quarter ending 2016-09-30 was $0.00.
- Aclaris Therapeutics, Inc. stock issued during period, value, acquisitions for fiscal 2018 was $2.21M, a 77.11% decline from fiscal 2017.
- Aclaris Therapeutics, Inc. stock issued during period, value, acquisitions for fiscal 2017 was $9.68M, a 310.83% increase from fiscal 2016.
- Aclaris Therapeutics, Inc. stock issued during period, value, acquisitions for fiscal 2016 was $2.35M.
| Period end | Stock Issued During Period, Value, Acquisitions 3 month | Stock Issued During Period, Value, Acquisitions 12 month |
|---|---|---|
| 2018-12-31 | $2.21M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $9.68M 10-K · filed 2020-02-25 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $2.35M 10-K · filed 2019-03-18 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |